Table 2.
Descriptive statistics of disease outcomes in the matched cohorts of patients.
| Outcomes | Patients with asthma | Patients with COPD | ||
| BF Spiromax (n=253) |
BF Turbuhaler (n=743) | BF Spiromax (n=132) |
BF Turbuhaler (n=348) | |
| % Risk domain control | 73.1 | 68.0 | 40.2 | 37.1 |
| No. of exacerbations (SD) | 0.3 (0.7) | 0.4 (0.7) | 1.1 (1.4) | 1.0 (1.4) |
| % Treatment stability | 72.7 | 66.9 | 39.4 | 37.1 |
| SABA average daily dose (SD) | 1.4 (1.9) | 1.5 (2.9) | 2.6 (2.9) | 2.4 (2.3) |
| No. of SABA inhalers (SD) | 5.1 (6.8) | 5.5 (10.7) | 9.5 (11.0) | 8.7 (8.5) |
| No. of antibiotics prescriptions (SD) | 0.2 (0.7) | 0.4 (0.8) | 0.7 (1.1) | 0.8 (1.1) |
| No. of acute OCS courses (SD) | 0.3 (0.7) | 0.3 (0.7) | 1.0 (1.7) | 0.9 (1.3) |
| FDC ICS average daily dose (SD) | 382.1 (351.3) | 505.3 (585.0) | 555.3 (427.1) | 561.8 (646.1) |
| No. of FDC inhalers (SD) | 14.0 (8.9) | 10.8 (5.6) | 15.0 (6.7) | 11.9 (5.4) |
| No. of respiratory A&E attendances (SD) | 0.0 (0.1) | 0.0 (0.1) | 0.0 (0.2) | 0.1 (0.4) |
| No. of probable respiratory inpatient hospitalisations (SD) | 0.0 (0.1) | 0.0 (0.1) | 0.1 (0.4) | 0.1 (0.5) |
| No. of definite respiratory inpatient hospitalisations (SD) | 0.0 (0.1) | 0.0 (0.1) | 0.0 (0.3) | 0.1 (0.4) |
| % Probable pneumonia* | 0.0 | 0.0 | 3.0 | 2.3 |
| % Definite pneumonia* | 0.0 | 0.0 | 2.3 | 0.6 |
A&E, accident and emergency; BF, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; FDC, fixed-dose combination; ICS, inhaled corticosteroid; OCS, oral corticosteroid; SABA, short-acting β2 agonist.
*A pneumonia event was defined as having a Read coded diagnosis (probable pneumonia), or a Read coded diagnosis with a hospital admission or chest X-ray within 1 month (definite pneumonia).